These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38002270)

  • 21. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
    Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
    J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
    Wang H; Zhou W; Zheng Z; Zhang P; Tu B; He Q; Zhu WG
    DNA Repair (Amst); 2012 Feb; 11(2):146-56. PubMed ID: 22112863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
    Schäfer C; Göder A; Beyer M; Kiweler N; Mahendrarajah N; Rauch A; Nikolova T; Stojanovic N; Wieczorek M; Reich TR; Tomicic MT; Linnebacher M; Sonnemann J; Dietrich S; Sellmer A; Mahboobi S; Heinzel T; Schneider G; Krämer OH
    Cell Signal; 2017 Jan; 29():218-225. PubMed ID: 27838375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2.
    Zhang J; Kan S; Huang B; Hao Z; Mak TW; Zhong Q
    Genes Dev; 2011 Dec; 25(24):2610-8. PubMed ID: 22016339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis.
    Hamam HJ; Palaniyar N
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31083537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
    Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
    Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
    Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
    J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
    Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
    Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
    Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
    Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC inhibitors: roles of DNA damage and repair.
    Robert C; Rassool FV
    Adv Cancer Res; 2012; 116():87-129. PubMed ID: 23088869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics.
    Yu X; Kogan S; Chen Y; Tsang AT; Withers T; Lin H; Gilleran J; Buckley B; Moore D; Bertino J; Chan C; Kimball SD; Loh SN; Carpizo DR
    Clin Cancer Res; 2018 Sep; 24(18):4505-4517. PubMed ID: 29914895
    [No Abstract]   [Full Text] [Related]  

  • 38. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53.
    Boudreau HE; Ma WF; Korzeniowska A; Park JJ; Bhagwat MA; Leto TL
    Oncotarget; 2017 Jul; 8(27):44379-44397. PubMed ID: 28574838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.